Analyst Consensus ?
1 unmapped firm rating excluded from the percentages.
GE Aerospace · GE · FY2026 Q2 · Calendar Q3 2026
GE Aerospace's Q2 2026 results reinforce its position as a pure-play aerospace engine maker with a growing services franchise. Revenue grew 24% YoY with orders up 17%, and management raised full-year guidance across both segments. The LEAP engine backlog and a $170B services backlog provide multi-year revenue visibility. However, rising spare-parts delinquency (up 20% sequentially) and supply-chain capacity constraints temper near-term enthusiasm, as evidenced by the stock's 3.5% abnormal decline on the report despite the beat and raise. The subsequent 4.6% drift higher suggests the initial sell-off was an overreaction to supply-chain concerns rather than a signal of fundamental weakness.
Based in Evendale, Ohio, GE Aerospace is a prominent American aviation enterprise with roots tracing back to its 1878 founding by Thomas Alva Edison. The company specializes in manufacturing and supplying jet and turboprop engines, along with integrated systems, for an extensive range of aircraft, including those in commercial, military, business, and general aviation use. Its robust brand lineup features Avio Aero, Unison, GE Additive, and Dowty Propellers. GE Aerospace organizes its activities into two core segments: Commercial Engines & Services, and Defense & Propulsion Technologies. The Commercial Engines & Services division oversees the design, development, production, and maintenance of jet engines for commercial airframes, business aviation, and aeroderivative applications. Meanwhile, the Defense & Propulsion Technologies segment is dedicated to providing vital engines and critical systems for defense-related aerospace needs.
1 unmapped firm rating excluded from the percentages.
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Aug 11, 2026. Not an FN2 forecast.
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Bernstein | Outperform | Outperform | Maintain | Jul 23, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Jul 20, 2026 |
| UBS | Buy | Buy | Maintain | Jul 17, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Jul 17, 2026 |
| TD Cowen | Buy | Buy | Maintain | Jul 13, 2026 |
| Susquehanna | Positive | Positive | Maintain | Jul 9, 2026 |
| Jefferies | Buy | Buy | Maintain | Jul 2, 2026 |
| Citigroup | Buy | Buy | Maintain | Jul 1, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Apr 22, 2026 |
| B of A Securities | Buy | Buy | Maintain | Oct 27, 2025 |
| Barclays | Overweight | Overweight | Maintain | Jul 23, 2025 |
| Wells Fargo | Overweight | Overweight | Maintain | Apr 24, 2025 |
| Deutsche Bank | Buy | Buy | Maintain | Jan 2, 2025 |
| Goldman Sachs | Buy | Buy | Maintain | Apr 24, 2024 |
| Argus Research | Buy | Buy | Maintain | Apr 24, 2024 |
| Oppenheimer | Perform | Perform | Maintain | Mar 5, 2024 |
| Credit Suisse | Outperform | Outperform | Maintain | Jul 27, 2022 |
| Wolfe Research | Outperform | Outperform | Maintain | May 11, 2022 |
| DZ Bank | Hold | Sell | Upgrade | Dec 16, 2020 |
| Gordon Haskett | Hold | Underperform | Upgrade | Feb 7, 2020 |
| Vertical Research | Hold | Buy | Downgrade | Feb 1, 2019 |
| Argus | Buy | Hold | Upgrade | Jan 31, 2019 |
| Bank of America | Neutral | Neutral | Maintain | Jul 27, 2018 |
| Gabelli & Co. | Buy | Buy | Maintain | May 14, 2018 |
| Stifel Nicolaus | Hold | Hold | Maintain | Apr 27, 2018 |
| Langenberg & Company | Buy | Hold | Upgrade | Nov 13, 2017 |
| Standpoint Research | Hold | Sell | Upgrade | Jun 29, 2017 |
| Cowen & Co. | Perform | Market Perform | Maintain | Jun 7, 2016 |
| William Blair | Outperform | Market Perform | Upgrade | Oct 13, 2015 |
| LBBW Research | Buy | Hold | Upgrade | Jan 26, 2015 |
| Stifel | Buy | Buy | Maintain | Sep 17, 2014 |
| Nomura | Neutral | Neutral | Maintain | Nov 18, 2013 |
| Tigress Financial | Neutral | Neutral | Maintain | Mar 6, 2013 |
| Hilliard Lyons | Long Term Buy | Maintain | Oct 19, 2012 | |
| Bank oferica | Neutral | Neutral | Maintain | Apr 4, 2012 |
Upside is calculated against the persisted current price $368.06. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Deutsche Bank | Analyst unavailable | $450 | $361.52 | +22.3% | Jul 27, 2026 |
| Bernstein | Analyst unavailable | $421 | $341.19 | +14.4% | Jul 23, 2026 |
| Wells Fargo | Analyst unavailable | $390 | $348.83 | +6.0% | Jul 20, 2026 |
| Goldman Sachs | Noah Poponak | $410 | $348.83 | +11.4% | Jul 20, 2026 |
| UBS | Gavin Parsons | $435 | $345.73 | +18.2% | Jul 17, 2026 |
| RBC Capital | Ken Herbert | $400 | $353.73 | +8.7% | Jul 15, 2026 |
| Susquehanna | Analyst unavailable | $430 | $361.02 | +16.8% | Jul 9, 2026 |
| Jefferies | Sheila Kahyaoglu | $455 | $380.41 | +23.6% | Jul 2, 2026 |
| Seaport Global | Analyst unavailable | $375 | $314.49 | +1.9% | May 26, 2026 |
| RBC Capital | Ken Herbert | $355 | $285.28 | -3.5% | May 20, 2026 |
| Jefferies | Analyst unavailable | $365 | $284.6 | -0.8% | Apr 26, 2026 |
| Morgan Stanley | Analyst unavailable | $425 | $334.74 | +15.5% | Feb 20, 2026 |
| Deutsche Bank | Analyst unavailable | $387 | $293.42 | +5.1% | Jan 23, 2026 |
| UBS | Analyst unavailable | $374 | $295 | +1.6% | Jan 23, 2026 |
| Susquehanna | Analyst unavailable | $380 | $322.67 | +3.2% | Jan 15, 2026 |
| UBS | Analyst unavailable | $368 | $323.26 | -0.0% | Jan 15, 2026 |
| UBS | Gavin Parsons | $366 | $306.63 | -0.6% | Oct 22, 2025 |
| Deutsche Bank | Analyst unavailable | $350 | $301.74 | -4.9% | Oct 8, 2025 |
| RBC Capital | Ken Herbert | $275 | $248.87 | -25.3% | Jun 3, 2025 |
| Argus Research | John Eade | $250 | $204.11 | -32.1% | Feb 3, 2025 |
| RBC Capital | Ken Herbert | $200 | $176.66 | -45.7% | Oct 23, 2024 |
| Wells Fargo | Matthew Akers | $210 | $176.66 | -42.9% | Oct 23, 2024 |
| UBS | Chris Snyder | $230 | $176.66 | -37.5% | Oct 23, 2024 |
| Bernstein | Brendan Luecke | $225 | $191.16 | -38.9% | Oct 14, 2024 |
| Bernstein | Douglas Harned | $201 | $165.35 | -45.4% | Sep 10, 2024 |
| Deutsche Bank | Scott Deuschle | $209 | $161.92 | -43.2% | Jun 10, 2024 |
| UBS | Chris Snyder | $201 | $160.81 | -45.4% | May 23, 2024 |
| CFRA | Stewart Glickman | $181 | $160.81 | -50.8% | May 22, 2024 |
| Argus Research | John Eade | $170 | $156.61 | -53.8% | Apr 10, 2024 |
| Jefferies | Sheila Kahyaoglu | $180 | $155.95 | -51.1% | Apr 10, 2024 |
| Goldman Sachs | Noah Poponak | $190 | $156.52 | -48.4% | Apr 9, 2024 |
| Vertical Research | Jeffrey Sprague | $160 | $145.62 | -56.5% | Apr 4, 2024 |
| RBC Capital | Ken Herbert | $160 | $145.62 | -56.5% | Apr 4, 2024 |
| Deutsche Bank | Scott Deuschle | $190 | $136.47 | -48.4% | Apr 3, 2024 |
| Wolfe Research | Myles Walton | $162 | $136.47 | -56.0% | Apr 3, 2024 |
| Wells Fargo | Matthew Akers | $200 | $173.55 | -45.7% | Mar 27, 2024 |
| J.P. Morgan | Seth Seifman | $136 | $131.23 | -63.0% | Jan 23, 2024 |
| Citigroup | Analyst unavailable | $100 | $81.45 | -72.8% | Dec 9, 2022 |
| RBC Capital | Analyst unavailable | $98 | $82.49 | -73.4% | Dec 9, 2022 |
| Deutsche Bank | Analyst unavailable | $94 | $85.23 | -74.5% | Dec 5, 2022 |
| Barclays | Analyst unavailable | $78 | $62.54 | -78.8% | Oct 3, 2022 |
| UBS | Analyst unavailable | $87 | $73.98 | -76.4% | Aug 4, 2022 |
| Credit Suisse | Analyst unavailable | $84 | $70.56 | -77.2% | Jul 27, 2022 |
| Deutsche Bank | Analyst unavailable | $90 | $62.14 | -75.5% | Jul 13, 2022 |
| Wells Fargo | Analyst unavailable | $72 | $63.02 | -80.4% | Jul 13, 2022 |
| Morgan Stanley | Joshua Pokrzywinski | $95 | $63.54 | -74.2% | Jul 12, 2022 |
| Barclays | Analyst unavailable | $81 | $63 | -78.0% | Jul 8, 2022 |
| Wells Fargo | Joseph O’Dea | $74 | $62.03 | -79.9% | Jul 5, 2022 |
| Goldman Sachs | Analyst unavailable | $82 | $64.54 | -77.7% | Jun 23, 2022 |
| Jefferies | Saree Boroditsky | $80 | $74.78 | -78.3% | Jun 10, 2022 |
| Morgan Stanley | Joshua Pokrzywinski | $100 | $77 | -72.8% | Jun 7, 2022 |
| Barclays | Julian Mitchell | $96 | $77.01 | -73.9% | May 26, 2022 |
| Morgan Stanley | Analyst unavailable | $112 | $76.6 | -69.6% | May 17, 2022 |
| Deutsche Bank | Nicole DeBlase | $107 | $74.76 | -70.9% | May 13, 2022 |
| Wolfe Research | Nigel Coe | $107 | $72.83 | -70.9% | May 12, 2022 |
| Morgan Stanley | Analyst unavailable | $115 | $76.86 | -68.8% | Apr 29, 2022 |
| Credit Suisse | John Walsh | $102 | $74.55 | -72.3% | Apr 29, 2022 |
| Deutsche Bank | Nicole DeBlase | $118 | $90.83 | -67.9% | Apr 17, 2022 |
| Barclays | Julian Mitchell | $115 | $92.02 | -68.8% | Apr 4, 2022 |
| Cowen & Co. | Gautam Khanna | $110 | $92.28 | -70.1% | Mar 12, 2022 |
| Credit Suisse | John Walsh | $116 | $88.15 | -68.5% | Mar 8, 2022 |
| Wolfe Research | Nigel Coe | $127 | $92.69 | -65.5% | Feb 21, 2022 |
| Bank of America Securities | Andrew Obin | $132 | $92.02 | -64.1% | Jan 28, 2022 |
| Goldman Sachs | Joe Ritchie | $124 | $89.24 | -66.3% | Jan 26, 2022 |
| J.P. Morgan | Stephen Tusa | $55 | $89.24 | -85.1% | Jan 26, 2022 |
| Bernstein | Brendan Luecke | $120 | $99.33 | -67.4% | Jan 10, 2022 |
| Jefferies | Saree Boroditsky | $100 | $89.9 | -72.8% | Dec 20, 2021 |
| DZ BANK AG | Robert Czerwensky | $140 | $102.65 | -62.0% | Aug 4, 2021 |
Track every rating change on GE the moment it posts. Free to start.
Start freeFollow GE with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEPS of $2.02 beat consensus of $1.86 by 8.6%, while revenue of $12.63B exceeded estimates of $11.88B by 6.3%. Orders grew 17% and operating profit rose 18% YoY. Management raised full-year guidance: CES revenue growth to approximately 20%, DPT to low-double-digits, and EPS to $7.65 to $7.85. The stock fell 3.5% on an abnormal basis despite the beat, with volume 39% above baseline, before drifting 4.6% higher in subsequent sessions. The pullback appears driven by concerns over rising spare-parts delinquency (up 20% sequentially) and supply-chain capacity limits rather than fundamental deterioration. Notably, this quarter's guidance raise marks a shift from Q1, when guidance was merely maintained amid geopolitical uncertainty.
Full-year guidance was raised across the board, a notable upgrade from the prior quarter when guidance was maintained. CES revenue growth is now expected at approximately 20%, DPT growth at low-double-digits, and full-year EPS guidance set at $7.65 to $7.85. Capex outlook remains increasing, with continued investments in MRO capacity expansion at Celma and the new MTU Fort Worth facility, LEAP durability kit industrialization for early 2027, and hybrid-electric EPFD demonstrator development. The raise signals management's growing confidence in aftermarket demand resilience and LEAP engine momentum despite lingering macro uncertainty.
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.